Nanopore Based Diagnostics

Long read sequencing for Clinical diagnostics is rapidly evolving and provides insights into genetic variations like structural variations, CNVs and methylation in hard to sequence regions using conventional short read technologies. Unambiguous mapping of long-read couple with solutions that enable targeted capture without the need for PCR opens up the possibility to exploit it to transform health care genomics. A whole range of products cater to different scales and needs of diagnostic labs to handle few hundred to several thousand Human genomes or targeted sequencing.


Read More


Read More


Read More


  • Scalable platforms to suit all requirements and generate new insights into health and disease from research into cancer, immunology, neuroscience and reproductive health, pharmacology, the microbiome and infectious diseases, and many other areas of biomedical research.
  • Offers comprehensive, real-time insights into infectious disease samples from pathogen identification and antimicrobial resistance (AMR) profiling to the assembly of high-quality genomes and variant identification
  • Delivers immediate access to the critical genomic epidemiology data required for effective control of infectious disease outbreaks.
  • Allows sequencing in the lab or at sample source with powerful portable and high- throughput devices at a scale to suit your needs

LamPORE Assay

A rapid, low-cost, highly scalable diagnostic test for SARS CoV-2. LamPORE assay is designed in such a way that it can be deployed in high-throughput traditional lab set-up and local setting as well.

  • Rapid & Scalable
  • Sensitive & specific – 99.1% sensitivity; 99.6% specificity
  • Accurate – Targets three highly conserved SARS-CoV-2 genes, reducing inconclusive results and
    requirement for repeat testing
  • Cost- efficient – Run the assay on already available Nanopore sequencer purchasing only the required consumables

We can create LamPORE assay for multiple disease like Zika, Ebola etc.,

    Enquiry Form